Published in Biotech Business Week, March 13th, 2006
The melanoma trial is a 50 patient multicenter study. The first dosing took place at the Mary Crowley Medical Research Center, Dallas, Texas. The principal investigator is John Nemuniatis. The primary endpoint of the study is tumor response rate with secondary endpoints including time to disease progression and median survival time.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.